Please assess the completion status of the following clinical trial:

Trial Title: To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 ;~* Total bilirubin ≥8 mg/dL;~* Medical history of alcohol abuse with evidence of a causal and temporal (\<6 weeks) relationship to the use of alcohol and hospital admission for this episode of sAAH;~* Maddrey score ≥32~* A clinical diagnosis of severe acute alcoholic hepatitis (sAAH);~* Subject must have liver biopsy or in investigator's opinion, if risk is too great to perform liver biopsy, then clinical diagnosis is sufficient;~* Subject must be a Lille score failure (Lille score \>0.45) as defined in this study.~Exclusion Criteria:~* Platelet count \<50,000/mm3;~* International Normalization Ratio (INR) \>3.0;~* MELD score \>35;~* Evidence of infection unresponsive to antibiotics;~* Evidence of jaundice for \>3 months;~* Hospital admission for any episodes of liver decompensation not related to sAAH, (other than this episode of sAAH) within the past 2 months;~* Evidence of hemodynamic instability;~* Evidence of active bleeding or of major hemorrhage defined as requiring ≥2 units of packed red blood cells to maintain a stable hemoglobin occurring within 48 hours of Screening;~* Evidence of occlusive portal vein thrombosis impairing hepatopetal flow, or evidence of bile duct obstruction;~* Evidence by physical exam, history, or laboratory evaluation of significant concomitant disease with expected life expectancy of less than 3 months;~* Clinical evidence of liver size reduction due to cirrhosis, unless Investigator interpretation of the clinical evidence indicates liver size of \<10 cm or volume of \<750 cc is not considered reduced for the individual subject;~* Chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks (not classified as hepatorenal syndrome);~* Uncontrolled seizures;~* Positive serologies for viral hepatitis B or C;~* Pregnancy as determined by β-human chorionic gonadotropin (HCG) results;~* Participation in another investigational drug, biologic, or device study within one month of enrollment, except for observational studies (the observational study setting should not affect the safety and/or efficacy of the VTI-210 clinical trial);~* Currently listed or scheduled for liver transplant during the 90-day study period;~* Previous liver transplant;~* Previous participation in a clinical trial involving ELAD;~* Has a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or local equivalent) or any other Advanced Directive limiting Standard of Care in place (the DNR/DNI criterion is not applicable in the UK);~* Refusal to participate in the VTI-210E follow-up study;~* Is unable to provide an address for follow-up home visits.~And other inclusion/exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELAD (plus Standard of Care) (Type: EXPERIMENTAL): ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
- Standard of Care (Control) (Type: OTHER): Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy